Literature DB >> 19275467

Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model.

Fumiaki Oka1, Hirosuke Fujisawa, Sadahiro Nomura, Koji Kajiwara, Shoichi Kato, Masami Fujii, Hiroshi Izuma, Kanako Uozumi, Toshikazu Gondo, Michiyasu Suzuki.   

Abstract

Thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) after ischemic stroke is effective. However, rtPA potentiates neuronal damage, and interactions between rtPA and thrombolysis products (TLP) have been reported to play a role in this. In the present study we investigated the mechanisms underlying rtPA- and TLP-induced neurotoxicity. Adult male Sprague-Dawley rats were subjected to 60-min intraluminal middle cerebral artery (MCA) occlusion, and then treated with rtPA (10 mg/kg), TLP, or saline. To evaluate the effects of a free radical scavenger, treatment with edaravone and TLP was evaluated. To investigate the role of red blood cells (RBCs), RBC-depleted TLP was used. Neurological deficit scores, infarct volume, and immuno-histochemical localization of oxidative end products for lipid and DNA (4-hydroxy-2-nonenal [4-HNE] and 8-hydroxy-deoxyguanosine [8-OHdG]) were evaluated. TLP increased the infarct volume, worsened the neurological deficits, and increased accumulations of 4-HNE and 8-OHdG. Edaravone treatment significantly reduced the lesion volume and improved the neurological score. Both infarct volume and accumulation of oxidative products were significantly suppressed when RBC-depleted TLP was used. In this mechanical model of MCA occlusion, rtPA-induced TLP, especially in the presence of RBCs, contributed to neuronal damage by accelerating free radical injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275467     DOI: 10.1089/neu.2008.0768

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  3 in total

Review 1.  The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.

Authors:  George W J Harston; Brad A Sutherland; James Kennedy; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

Review 2.  Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis.

Authors:  Mei-Xue Dong; Qing-Chuan Hu; Peng Shen; Jun-Xi Pan; You-Dong Wei; Yi-Yun Liu; Yi-Fei Ren; Zi-Hong Liang; Hai-Yang Wang; Li-Bo Zhao; Peng Xie
Journal:  PLoS One       Date:  2016-07-07       Impact factor: 3.240

3.  Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion.

Authors:  Linlei Zhang; Shasha Xu; Xiaoxiao Wu; Jiaou Chen; Xiaoling Guo; Yungang Cao; Zheng Zhang; Jueyue Yan; Jianhua Cheng; Zhao Han
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.